Alto Neuroscience Inc. (ANRO)
NYSE: ANROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANRO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.02B
- EPS (TTM)
- -$2.32
- Dividend yield
- None
- 52-week range
- 12.51 – 37.48
- Day range
- 24.40 – 26.48
- Volume / Avg
- 522.53K / 614.92K
- Beta
- —
- Shares outstanding
- 40.11M
52-week range
ANRO stock today
Shares of Alto Neuroscience (ANRO) finished lower on Nov 20 at $25.37, a drop of 4.30% or $1.14 per share, versus the S&P 500's 3.70% decline. At this level, ANRO sits in the middle of its 52-week range of $12.51 to $37.48: 32.3% below the high, set on Aug 25, 2026 and 102.8% above the low. ANRO is up 42.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 91.5%.
Alto Neuroscience has posted a net loss over the last twelve months (EPS of -$2.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Alto Neuroscience
Company profileAlto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Amit Etkin M.D., Ph.D.
- Headquarters
- Mountain View, CA
- Employees
- 68
- IPO year
- 2024
- Website
- altoneuroscience.com
Financial highlights
Full financialsAlto Neuroscience reported a net loss of $63.2 million, compared with a loss of $61.4 million a year earlier. Diluted earnings per share came in at -$2.19.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-63.24M | $-61.43M | $-36.30M |
| EPS (diluted) | $-2.19 | $-2.50 | $-9.73 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$38.67+52.42%
- Strong buy 0
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.54 vs $-0.60
- Surprise
- +10.00%
ANRO news
All ANRO news- Is UnitedHealth Group (UNH) Stock Outpacing Its Medical Peers This Year?NasdaqUNH, ANRO
- Alto Neuroscience GAAP EPS of -$0.54 beats by $0.13Seeking Alpha
- Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business HighlightsBusiness Wire
- Here's Why You Should Add ANRO Stock to Your Portfolio NowNasdaqANRO, AMRN, CORT, ALDX
- Are Medical Stocks Lagging Cardinal Health (CAH) This Year?NasdaqCAH, ANRO
Alto Neuroscience peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CTYCity Therapeutics Inc. | 19.32 | +5.29% | $1.03B | vs ANRO |
| NKTRNektar Therapeutics | 30.20 | -7.19% | $1.03B | vs ANRO |
| OMEROmeros Corporation | 13.21 | -5.71% | $983.66M | vs ANRO |
| JBIOJade Biosciences Inc. | 15.31 | +1.66% | $1.06B | vs ANRO |
| SPTXSeaport Therapeutics Inc. | 18.05 | -1.47% | $966.23M | vs ANRO |
| CYRXCryoPort Inc. | 19.05 | -2.56% | $964.87M | vs ANRO |
| KARDKardigan Inc. | 11.54 | -7.83% | $1.08B | vs ANRO |
| MLTXMoonLake Immunotherapeutics Class A | 11.07 | +0.36% | $942.13M | vs ANRO |
Indexes, lists and sector
Alto Neuroscience stock FAQ
What is Alto Neuroscience's stock price today?
ANRO last traded at $25.37 as of Nov 20, 4:00 PM EST, down 4.30% on the day. Prices are delayed at least 15 minutes.
Who is Alto Neuroscience's CEO?
Dr. Amit Etkin M.D., Ph.D. is the chief executive officer of Alto Neuroscience Inc., which has about 68 employees.
What is the ANRO 52-week high?
The 52-week high for ANRO is $37.48 and the 52-week low is $12.51. The stock is currently 32.3% below its high.